Henner Hanssen Selected Research

Lipids

1/2023	Effects of a 5-week intake of erythritol and xylitol on vascular function, abdominal fat and glucose tolerance in humans with obesity: a pilot trial.
1/2022	A 4-week high-AGE diet does not impair glucose metabolism and vascular function in obese individuals.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Henner Hanssen Research Topics

Disease

9	Hypertension (High Blood Pressure) 01/2024 - 03/2010
6	Obesity 01/2023 - 01/2011
4	Cardiovascular Diseases (Cardiovascular Disease) 12/2022 - 01/2016
3	Inflammation (Inflammations) 01/2022 - 08/2009
3	Type 2 Diabetes Mellitus (MODY) 01/2022 - 07/2019
2	Insulin Resistance 01/2024 - 01/2022
2	Chronic Kidney Failure (Chronic Renal Failure) 12/2022 - 04/2019
2	Pediatric Obesity 01/2021 - 01/2018
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 07/2019 - 01/2019
2	Heart Failure 01/2019 - 10/2009
2	Atherosclerosis 01/2019 - 08/2009
2	Overweight 01/2018 - 01/2018
2	Necrosis 04/2017 - 02/2011
1	Frailty 04/2024
1	COVID-19 11/2023
1	Critical Illness (Critically Ill) 12/2022
1	Infections 12/2022
1	Pregnancy-Induced Hypertension (Hypertension, Pregnancy Induced) 02/2022
1	Pre-Eclampsia (Preeclampsia) 02/2022
1	Hypertensive Retinopathy 01/2022
1	Cognitive Dysfunction 01/2022
1	Chronic Disease (Chronic Diseases) 01/2020
1	Depressive Disorder (Melancholia) 11/2018
1	Rheumatic Diseases (Rheumatism) 01/2018
1	Prehypertension 06/2016
1	Atrial Remodeling 01/2016
1	Stroke (Strokes) 03/2010

Drug/Important Bio-Agent (IBA)

15	Retinaldehyde (Retinal)IBA 01/2024 - 03/2010
10	Biomarkers (Surrogate Marker)IBA 01/2024 - 02/2011
4	Oxygen (Dioxygen)IBA 01/2024 - 01/2018
3	Glucose (Dextrose)FDA LinkGeneric 01/2024 - 07/2019
3	Antihypertensive Agents (Antihypertensives)IBA 01/2024 - 01/2022
2	LipidsIBA 01/2023 - 01/2022
2	Advanced Glycation End ProductsIBA 01/2022 - 01/2020
2	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2020 - 07/2019
2	Sitagliptin Phosphate (Januvia)FDA Link 01/2020 - 07/2019
2	Clostridium perfringens epsilon-toxinIBA 01/2020 - 10/2009
1	Triglycerides (Triacylglycerol)IBA 01/2024
1	CholesterolIBA 01/2024
1	Uric Acid (Urate)IBA 01/2023
1	ErythritolIBA 01/2023
1	EnzymesIBA 01/2023
1	CreatinineIBA 01/2023
1	XylitolIBA 01/2023
1	Untranslated RNA (Noncoding RNA)IBA 12/2022
1	Histones (Histone)IBA 12/2022
1	Dietary Advanced Glycation End ProductsIBA 01/2022
1	6-chloro-2-(1-piperazinyl)pyrazine (CPP)IBA 01/2021
1	PlacebosIBA 01/2020
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2020
1	tocilizumab (atlizumab)FDA Link 01/2020
1	Glucagon-Like Peptide 1 (GLP 1)IBA 07/2019
1	Hemoglobins (Hemoglobin)IBA 01/2019
1	Mydriatics (Cycloplegics)IBA 01/2019
1	C-Reactive ProteinIBA 04/2017
1	Cartilage Oligomeric Matrix ProteinIBA 04/2017
1	Interleukin-6 (Interleukin 6)IBA 04/2017
1	MicroRNAs (MicroRNA)IBA 01/2016
1	CytokinesIBA 01/2011
1	oxidized low density lipoproteinIBA 08/2009

Therapy/Procedure

2	Resistance Training 01/2022 - 01/2015
2	Endurance Training 01/2022 - 04/2017
1	Exercise Therapy (Therapy, Exercise) 04/2024
1	Therapeutics 07/2023
1	Secondary Prevention 12/2022
1	Renal Dialysis (Hemodialysis) 01/2022